<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01483534</url>
  </required_header>
  <id_info>
    <org_study_id>CLP-001</org_study_id>
    <nct_id>NCT01483534</nct_id>
  </id_info>
  <brief_title>Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation</brief_title>
  <acronym>IPS-I</acronym>
  <official_title>Evaluation of the Innovative Pulmonary Solutions (IPS) System for Targeted Lung Denervation (TLD) Therapy in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) - A Safety Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nuvaira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nuvaira, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety of Targeted Lung Denervation Therapy (or
      TLD TherapyTM) in patients suffering from COPD. Technical feasibility of the IPS SystemTM
      will also be evaluated through confirmation of successful application of TLD Therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Safety Endpoint</measure>
    <time_frame>365 days post procedure</time_frame>
    <description>Safety will be evaluated as freedom from documented and sustained worsening of COPD directly attributable to the investigational device or procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Technical Feasibility</measure>
    <time_frame>At time of Treatment</time_frame>
    <description>The ability to access the target treatment area and deliver RF energy to the target treatment site.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>Targeted Lung Denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Targeted Lung Denervation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TLD Therapy (IPS SystemTM)</intervention_name>
    <description>Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.</description>
    <arm_group_label>Targeted Lung Denervation</arm_group_label>
    <other_name>TLD Therapy, Targeted Lung Denervation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  FEV1 30% to 60%

          -  FEV1/FVC &lt;70%

          -  Prior smoker (at least 10 pack years)

          -  Quit smoking for at least 6 months

        Exclusion Criteria:

          -  Pulmonary hypertension, peripheral edema suggesting CHF or polycythemia

          -  Prior lung transplant, LVR, LVRS, median sternotomy, bullectomy or lobectomy

          -  Pulmonary nodule requiring surgery

          -  Presence of implantable electronic devices

          -  Active respiratory infection within recent weeks

          -  COPD exacerbation within recent weeks

          -  Recent Myocardial infarction (MI)

          -  Recent and unstable or life threatening arrhythmia

          -  Malignancy treated with radiation or chemotherapy within the last 2 years

          -  Presence or clinical diagnosis of other respiratory diseases other than COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk-Jan Slebos, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Medical Center Groningen (UMCG)</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Panorama Medi-Clinic</name>
      <address>
        <city>Panorama</city>
        <state>Cape Town</state>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stellenbosch University</name>
      <address>
        <city>Capetown</city>
        <zip>7505</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>South Africa</country>
  </location_countries>
  <link>
    <url>http://thorax.bmj.com/content/early/2015/03/03/thoraxjnl-2014-206146</url>
    <description>Targeted lung denervation for moderate to severe COPD: a pilot study.</description>
  </link>
  <results_reference>
    <citation>Slebos DJ, Klooster K, Koegelenberg CF, Theron J, Styen D, Valipour A, Mayse M, Bolliger CT. Targeted lung denervation for moderate to severe COPD: a pilot study. Thorax. 2015 May;70(5):411-9. doi: 10.1136/thoraxjnl-2014-206146. Epub 2015 Mar 4.</citation>
    <PMID>25739911</PMID>
  </results_reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2011</study_first_submitted>
  <study_first_submitted_qc>November 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2011</study_first_posted>
  <last_update_submitted>September 22, 2016</last_update_submitted>
  <last_update_submitted_qc>September 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>Pulmonary</keyword>
  <keyword>Intervention</keyword>
  <keyword>Device</keyword>
  <keyword>Denervation</keyword>
  <keyword>Lung</keyword>
  <keyword>Holaira, Inc.</keyword>
  <keyword>Innovative Pulmonary Solutions, Inc.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

